185990-09-4

Basic information

• Product Name: tert-butyl 1-phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-oate
• Synonyms: tert-butyl 1-phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-oate
• CAS NO: 185990-09-4
• Molecular Weight: 486.603
• Mol File: 185990-09-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl 1-phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-oate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 1-phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-oate(185990-09-4)
• EPA Substance Registry System: tert-butyl 1-phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-oate(185990-09-4)

Safety Data

• Hazardous Substances Data: 185990-09-4(Hazardous Substances Data)

Upstream product

• 89346-82-7 2-<2-<2-<2-(benzyloxy)ethoxy>ethoxy>ethoxy>ethyl 4-methylbenzenesulfonate 
• 86259-87-2 1-phenyl-2,5,8,11-tetraoxatridecan-13-ol 
• 100-39-0 benzyl bromide 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 24342-68-5 1-phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-ol 
• 2615-15-8 pentaethylene glycol 

Downstream Products

• 185990-10-7 20-benzyloxy-3,6,9,12,15,18-hexaoxaeicosanoic acid 
• 1361209-04-2 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(benzyloxy)hexaethylene glycol acetylthymidine 
• 1361209-06-4 DoHu 
• 1530777-90-2 tert-butyl 20-(tosyloxy)-3,6,9,12,15,18-hexaoxicosanoate 
• 297162-49-3 tert-butyl 20-azido-3,6,9,12,15,18-hexaoxaeicosanoate 

Relevant articles and documents

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.